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Objectives The aim of this study was to demonstrate feasibility and short- and midterm clinical
outcomes with a new self-expanding transcatheter heart valve and motorized delivery system.
Background Reﬁning transcatheter aortic valve replacement with newly designed bioprostheses
and delivery systems is anticipated to facilitate the procedure, reduce the risk of complications, im-
prove outcomes, and widen applicability.
Methods The CENTERA valve (Edwards Lifesciences, Irvine, California) was implanted in 15 patients
with symptomatic severe aortic stenosis via femoral or axillary arterial percutaneous access. Patients
underwent transesophageal echocardiography during and transthoracic echocardiography and mul-
tidetector computed tomography before and after valve implantation. Clinical and echocardio-
graphic follow-up was obtained at 30 days and for the initial 10 patients after 1 year.
Results All 15 device implants were successful. Aortic valve area increased from 0.7  0.1 cm2 to
1.6  0.4 cm2 post-procedure (p  0.01) and 1.8  0.3 cm2 at 1 year. Mean transaortic gradient
decreased from 36.3  14.2 mm Hg to 10.6  5.4 mm Hg post-procedure (p  0.001) and
0.8  4.1 mm Hg at 1 year. Paravalvular aortic regurgitation at 30-day follow-up was none/
rivial in 3 (23%), mild in 9 (69%), and moderate in 1 (8%) patient. Four patients (27%) received
new permanent pacemaker. Survival was 87% at 30 days and 80% at 1 year. All surviving pa-
ients were in New York Heart Association functional class I (25%) or II (75%) at 1 year.
onclusions Transcatheter aortic valve replacement with the CENTERA transcatheter heart valve
nd motorized delivery system is feasible and can lead to good short- and midterm clinical and he-
odynamic outcomes. (J Am Coll Cardiol Intv 2013;6:301–7) © 2013 by the American College of
ardiology Foundation
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302Transcatheter aortic valve replacement (TAVR) has been
shown to reduce mortality in a randomized comparison with
medical treatment (1) and to be noninferior to surgical
aortic valve replacement in “high-risk operable” patients (2).
Further refinement of the procedure and current develop-
ments focus on minimizing access site complications, re-
ducing stroke risk, improving paravalvular sealing, avoiding
heart block, and facilitating easy and accurate prosthesis
implantation. Some of these issues might be addressed by
new delivery systems and transcatheter heart valves (THV).
We report early experience with the CENTERA self-
expanding valve and a unique motorized delivery system
(Edwards Lifesciences, Irvine, California).
Methods
The TAVR with the CENTERA THV was performed in
15 patients with symptomatic, severe aortic stenosis at 2
centers (St. Paul’s Hospital,
Vancouver, Canada, and the
Asklepios Klinik St. Georg,
Hamburg, Germany) between
2010 and 2012. All patients
were considered at increased risk
for surgery by a multidisciplinary
team including cardiac surgeons
and cardiologists, due to age,
frailty, comorbidities, or techni-
cal issues (e.g., adherent coro-
nary artery bypass grafts). All
patients gave written informed
consent for prospective data ac-
quisition approved by the local
ethics committee. Outcomes were
reported according to the Valve
Academic Research Consortium
guidelines (3) and the Risk, Injury, Failure, Loss, and End-
stage Kidney classification criteria (4). Patients underwent
pre-procedural aortic root, coronary and iliofemoral angiog-
raphy, transthoracic echocardiography (TTE), and multide-
tector computed tomography (MDCT). Before discharge
post-procedural TTE and MDCT were performed. The
MDCTs were read by a single radiologist (J.L.) at St. Paul’s
Hospital. The TTEs were read at the local site. Clinical and
echocardiographic follow-up was obtained at 30 days and 1
year. All data were prospectively collected in a dedicated
database.
Valve and delivery system. The CENTERA THV (Fig. 1)
is composed of a self-expandable, radiopaque, nitinol stent;
trileaflet bovine pericardial tissue valve (at annular level);
and polyethylene terephthalate fabric. The delivery catheter
is composed of an inner tubing assembly that contains the
guidewire lumen, a torque shaft and delivery cylinder
Abbreviations
and Acronyms
MDCT  multidetector
computed tomography
PAR  paravalvular
regurgitation
TAVR  transcatheter aortic
valve replacement
TEE  transesophageal
echocardiography
THV  transcatheter heart
valve
TTE  transthoracic
echocardiography
VARC  Valve Academic
Research Consortiumassembly, and an outer shaft (Fig. 2). These are attached toa control handle (Fig. 3). The guidewire lumen accommo-
dates a 0.035-inch guidewire. The self-expanding THV is
constrained in a metallic delivery cylinder. The catheter
incorporates a deflection mechanism to assist in traversing
the aortic arch and facilitate coaxial positioning within the
native valve. The 26-mm CENTERA was indicated, ac-
cording to the first-in-human protocol, if the aortic annulus
measured 20 to 23 mm by transesophageal echocardiogra-
phy (TEE) and the minimal internal lumen diameter of the
access vessel was 5.5 mm.
The detachable handle (Fig. 3) is a battery-powered,
motorized unit designed to provide sufficient torque to
advance or retract the delivery cylinder when loading and
deploying the THV. The handle has 2 buttons, allowing for
either valve deployment (big button) or valve loading (small
button).
Procedure. The TAVR with the 26-mm CENTERA was
erformed under general anesthesia (10 patients) or local
nesthesia (n5) and fluoroscopy as well as TEE guidance.
atients were pre-medicated with aspirin and clopidogrel.
n 18-F (initial 11 patients) or 16-F (last 4 transfemoral
atients) sheath was introduced into the common femoral
n11) or axillary artery (n4) after pre-closure sutures
ere inserted percutaneously (ProStar for transaxillary pa-
ients or Perclose ProGlide for transfemoral patients, Ab-
ott, Inc., Abbott Park, Illinois). The preferred access was
ransfemoral in Vancouver and trans-axillary in Hamburg.
re-implant balloon aortic valvuloplasty was performed
nder rapid ventricular pacing in all cases. The delivery
atheter was advanced over an Amplatz extra stiff 0.035-
Figure 1. CENTERA Self-Expanding Transcatheter Heart Valve
This self-expanding transcatheter heart valve incorporates a nitinol stent
frame (expanded height 20 mm), a polyethylene terephthalate skirt, and
bovine pericardial leaﬂets.
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303inch guidewire (Cook, Inc., Bloomington, Indiana) into the
left ventricle. Accurate positioning of the THV was ascer-
tained by aortic root angiograms with a pigtail catheter and
by TEE. Release of the THV was automatically performed
by motorized retraction of the deployment cylinder. After
the inflow and midportion of the THV were released and
accurate positioning was confirmed, rapid ventricular pacing
was initiated to facilitate final deployment of the THV (Fig.
4). The valve position was documented by aortic root
angiograms and TEE. The femoral or axillary access site
was closed percutaneously. Patients were monitored for at
least 72 h and discharged to continue on a regimen of
low-dose aspirin and 3 months of daily clopidogrel (75 mg)
unless oral anticoagulation was indicated.
Statistical analysis. All analyses were performed with the
SPSS software (version 17, SPSS, Inc., Chicago, Illinois).
Continuous variables are expressed as mean values  SD.
Categorical variables are described by frequencies and per-
centages. Comparisons of continuous variables were per-
formed by a paired t test. All statistical tests were 2-tailed,
and a value of p  0.05 was considered statistically
significant.
Figure 2. Delivery Catheter After Valve Is Loaded Into Delivery Capsule
The delivery catheter incorporates a hydrophilic outer shaft (A); a deﬂection a
within the annulus; the delivery cylinder (C), which restrains the valve in its cr
diameter is 14-F. The cylinder that encapsulates the valve at the end of the de
Figure 3. Motorized Delivery System Handle
The delivery system allows motorized single hand deployment or recaptur-
ing of the transcatheter heart valve by pushing the small or big button
(green), respectively.Results
Patients. Baseline clinical characteristics are outlined in
Table 1.
Clinical outcome. The CENTERA THV was successfully
deployed in all 15 patients with a fully percutaneous
approach. No patient required implantation of a second
THV, and there were no cases of valve migration or
embolization. In 1 patient the deployment was started too
high above the annulus, and after partial deployment the
THV was recaptured and immediately redeployed in the
correct position. Five patients (33%) underwent intra-
procedural post-dilation to address significant paravavular
regurgitation (PAR). This reduced PAR to trace in 2
patients and mild in the remainder. One patient developed
hemo-pericardium caused by pacing wire perforation, which
was percutaneously drained. Complete heart block directly
after valve deployment occurred in 4 patients (27%) and
necessitated permanent pacemaker implantation. Moderate-
to-severe PAR was seen in 1 patient at discharge. He under-
went post-dilation with a 25-mm balloon 30 days post-
procedure, which reduced PAR to mild. Short- and midterm
clinical outcomes are shown in Table 2.
Survival was 87% (13 of 15) at 30 days and 80% (8 of 10)
t 1-year follow-up. There were 2 in-hospital deaths, 1 due
o a cardiac arrest complicating renal failure (hyperkalemia
nd volume overload) on Day 8, and a second due to
n-hospital acquired pneumonia with respiratory failure on
ay 23. A third later death occurred on Day 49 in a patient
ho was initially doing well and was urgently readmitted
ith sepsis. Autopsies were performed on all 3 patients. The
eaths were found not to be valve-related (Fig. 5). However,
he 2 in-hospital deaths might be attributed to post-
rocedural complications. All patients, who were treated in
010, were in New York Heart Association functional class
(2 patients, 25%) or II (6 patients, 75%) at 1-year
ollow-up (8 of 10 patients alive after 12 months).
Echocardiography evaluation. Mean transaortic gradient
), which facilitates passage through aortic tortuosity and coaxial alignment
condition; and a tapered nose cone (D). The delivery system catheter outer
system has an outer diameter of 16-F.rea (B
impedwas reduced from 36.3 14.2 mm Hg to 10.6 5.4 mm Hg
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304post-procedure (p  0.001) and 10.8  4.1 mm Hg at 1
year. The aortic valve area increased from 0.7  0.1 cm2 to
.6 0.4 cm2 post-procedure (p 0.01) and 1.8 0.3 cm2
at 1-year. The PAR as assessed by TTE at 30-day follow-up
was none/trivial in 3 (23%) patients, mild in 9 (69%)
patients, and moderate in 1 (8%) patient. At 1-year
follow-up PAR was none/trivial in 2 (29%), mild in 4
(57%), and moderate in 1 (14%) patient (TTE at 1-year
follow-up completed in 7 patients).
MDCT evaluation. Three-dimensional evaluation of the aortic
Figure 4. Implantation Sequence
The optimal deployment projection is the perpendicular view where all 3 cusp
crossing the aortic valve (B). The transcatheter heart valve inside the delivery
deployed valve is ascertained by aortic root angiograms (D). Motorized retract
ment (F), the 3 connection points of the valve with the delivery system are revalve was performed before TAVR. The diameter of the native paortic annulus was 23.0  1.3 mm (mean of short and long
axis), with a diameter in the long axis of 25.4  1.8 mm and
n the short axis of 20.7  2.0 mm. Mean annular area was
.1  0.5 cm2. The MDCT was performed in 6 patients
ost-TAVR (DynaCT, Siemens, Inc., Erlangen, Germany)
Fig. 6). The MDCT is shown in Figure 7. The area of the
tent frame was 4.2 0.5 cm2 at the inflow, 4.7 0.7 cm2 in
he midportion, and 5.2  0.6 cm2 at the outflow. The THV
ccentricity (1-short axis/long axis) at the inflow level was
8.7  10.9% and did not differ from annular eccentricity
separately depicted in a line (A). A balloon valvuloplasty is performed after
er seen across the annulus (C). Accurate implant height of the partly
the delivery sheath leads to self-expansion of the valve (E). After full deploy-
(G). Accurate position and paravalvular sealing is documented (H and J).s are
cathet
ion ofre-TAVR 19.4  11.5% (p  0.903) (Fig. 7).
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305Discussion
We report the first-in-human experience with a new self-
expanding THV and motorized delivery system. A TAVR
with the CENTERA THV and motorized delivery system
was performed successfully in 15 patients with good hemo-
dynamic and clinical short- and midterm outcomes.
The CENTERA THV design shares some similarities
with current balloon-expandable THVs (SAPIEN and
SAPIEN XT, Edwards Lifesciences). All incorporate bo-
vine pericardial tissue leaflets and an internal polyethylene
terephthalate paravalvular seal and use relatively “short”
stent frames. The salient difference is the self-expanding
nitinol frame, with a flared inflow, narrower annular
segment, and a larger-diameter outflow. This shape is
designed to facilitate self-seating in the aortic annulus. In
comparison with most other self-expanding nitinol valves
the CENTERA THV does not extend into the ascending
aorta for anchoring or self-alignment.
The CENTERA fixation and alignment is dependent on
the self-seating stent frame but also on a radically different
Table 1. Baseline Characteristics (N15)
Age (yrs) 80.2 7.4
Male 5 (33%)
Diabetes 6 (40%)
Height (cm) 165.7 5.7
Weight (kg) 74.0 16.8
Prior CABG 4 (27%)
Prior myocardial infarction 5 (33%)
COPD 4 (27%)
Prior pacemaker 2 (13%)
STS PROM score (%) 7.3 4.0
NYHA pre-TAVR
I 0 (0%)
II 1 (7%)
III 13 (87%)
IV 1 (7%)
GFR (ml/min) 61.6 15.8
TEE aortic annulus diameter (mm) 21.9 1.2
TTE aortic annulus diameter (mm) 21.2 1.1
MDCT aortic annulus diameter (mm) 23.0 1.3
MDCT aortic annulus area (cm2) 4.1 0.5
AVA (cm2) 0.7 0.1
Transaortic gradient (mm Hg) 36.3 14.2
LVEF (%) 56.5 10.8
Moderately severe or severe mitral regurgitation 1 (7%)
Values are mean SD or n(%).
AVA  aortic valve area; CABG  coronary artery bypass graft; COPD  chronic obstructive
pulmonary disease; GFR  glomerular filtration rate; LVEF  left ventricular ejection fraction;
MDCT  multidetector computed tomography; STS PROM  Society of Thoracic Surgeons
predicted risk of mortality; TAVR  transcatheter aortic valve replacement; TEE  transesopha-
geal echocardiography; TTE transthoracic echocardiography; NYHA New York Heart Associ-
ation functional class.delivery system. The motorized system is designed toimprove the accuracy of deployment, without the high
forces and uncertainty of manual unsheathing. Unlike other
currently available systems, the THV does not tend to move
axially during deployment, because it is fixed to the rigid
inner catheter. The ability to flex the catheter contributes to
accurate positioning. Although these design elements seem
functional, the ability to position the THV coaxial to the
annulus was markedly limited by the prototypic catheter
system with a relatively long rigid distal segment. This
might have resulted in suboptimal positioning, expansion,
and sealing in the early experience.
Recapture. Ideally a transcatheter valve would be optimally
positioned on initial deployment; however, if positioning is
suboptimal then the ability to recapture and reposition or
retrieve would be a valuable option. The CENTERA valve
incorporates features intended to assure correct positioning
with the first attempt. However, it is apparent that further
modification of the delivery catheter will be necessary to
fully achieve this goal. Despite this, if initial valve deploy-
ment was suboptimal due to noncoaxial deployment, the
CENTERA THV has a feature to allow easy recapture with
the single hand operated motorized delivery system. This
will be a possibility as long as the aortic end of the stent
frame remains within the delivery cylinder. We used rapid
ventricular pacing during final deployment. Whether this is
necessary for stable THV release will be further studied.
Stent frame geometry. Currently available balloon expand-
ble stainless steel (SAPIEN) and cobalt chromium
Table 2. Cumulative In-Hospital, 30-Day, and 1-Year Outcomes
In-Hospital
Outcomes
30-Day
Outcomes
1-Year
Outcomes
Death 2 2 3
Myocardial infarction 0 0 0
Major stroke 0 0 0
Minor stroke 0 0 0
Transient ischemic attack 0 0 0
Major vascular complication 0 0 0
Minor vascular complication* 2 2 2
Major or life-threatening bleeding 1 1 1
Minor bleeding 1 1 1
Blood transfusions 2 2 2
Acute kidney injury (VARC) 1 1 1
Kidney failure (RIFLE) 3 3 3
Repeat procedure for valve-related
dysfunction
0 1 1
Permanent pacemaker implantation 4 4 4
Readmissions to hospital
Valve-related — 1 1
Cardiac — 1 2
Noncardiac — 1 5
*Covered stents were implanted in 2 patients with failed percutaneous closure.
RIFLE Risk, Injury, Failure, Loss, and End-stage Kidney classification; VARC Valve AcademicResearch Consortium.
d.
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306(SAPIEN XT) frames generate a relatively high radial force
and are generally circular despite the generally oval shape of
the native aortic annulus (5). Self-expanding nitinol frames
tend to generate a lower radial force and the inflow segment
is more likely to be asymmetrical (6–8). In vitro testing has
documented the potential for impaired hemodynamic per-
formance and reduced durability with asymmetrical, non-
circular valves (9). It has been suggested that THV designs
Figure 6. Post-Deployment 3-Dimensional Reconstruction
Post-deployment 3-dimensional reconstruction of the transcatheter heart
valve from a rotational aortic root angiogram (DynaCT, Siemens, Inc., Erlan-
gen, Germany) allows appreciation of the prosthesis geometry and its posi-
Figure 5. Postmortem Inspection
Images from an 87-year-old patient who died of pneumonia 23 days post-imp
(A) were identiﬁed as postmortem clots. Stent struts were well-apposed to the
raphy eccentricity index of the native annulus was 36% (higher index indicatin
on autopsy. The coronary ostia (B) were probed and documented unobstructetion in the aortic root and annulus.that incorporate supra-annular leaflets might mitigate
against these concerns (7). Most THVs are required to
undergo accelerated wear testing simulating an asymmetri-
cal deployment and have been found to function relatively
well within a certain range of under-expansion. To what
extent this assures clinical durability is unknown.
Heart block. Atrioventricular conduction delays after
TAVR have been more common with the self-expanding
CoreValve device (Medtronic, Minneapolis, Minnesota)
than the balloon-expandable SAPIEN THV (10). Al-
though no second- or third-degree heart block was observed
in the first-in-human experience (8) with the self-
expanding Portico valve (St. Jude Medical, Inc., St. Paul,
Minnesota), the rate of new permanent pacemaker im-
plantation in the early experience with the Lotus valve
(Boston Scientific, Inc., Natick, Massachusetts) was 36%
(REPRISE I [REpositionable Percutaneous Replace-
ment of Stenotic Aortic Valve Through Implantation of
Lotus Valve SystEm] trial, presented PCR London
Valves 2012). In the current trial with the CENTERA
THV the rate of permanent pacemaker insertion was
27%. Whether this is a general characteristic of self-
expanding valves is unknown. Specific device-related and
procedure-related factors might determine the likelihood
of mechanical injury to the interventricular septum.
Whether ongoing expansion of self-expanding valves is a
factor in the development of delayed block is speculative.
It does seem that procedural factors can be mitigated by
avoiding ventricular outflow tract positioning and exces-
sive oversizing. However, specific designs that favor
outflow tract position place excess pressure on the inter-
ventricular septum or require more oversizing might
ion. Autopsy showed a well-seated bioprosthesis. The thrombi on the valve
entricular outﬂow tract and aortic root. The multidetector computed tomog-
re oval shape). Eccentricity fell to 32% post-implant, which was appreciatedlantat
left v
g mopredispose to atrioventricular block.
sulus (
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307Study limitations and future directions. These results repre-
sent the initial learning curve with very novel approaches to
THV design and implantation. Modifications of the deliv-
ery system are planned to assure more reliable coaxial
engagement of the native annulus, a limitation of this
first-generation system. A reduced inflow diameter will be
incorporated into the next-generation CENTERA THV
with the goal, in part, to reduce mechanical stresses applied
to the interventricular septum and conduction system
(planed THV sizes 23, 26, and 29 mm). Further evaluation
of the enhanced system is anticipated with a possible CE
mark trial being completed by 2013.
Conclusions
Transcatheter aortic valve replacement with the CENTERA
THV and motorized delivery system is feasible and can lead to
good short- and midterm hemodynamic and clinical outcomes.
Reprint requests and correspondence: Dr. John Webb, Univer-
sity of British Columbia, St Paul’s Hospital, 1081 Burrard Street,
Room 476A, Vancouver, British Columbia, V6Z 1Y6, Canada.
E-mail: john.webb@vch.ca.
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